Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Above 50 Day Moving Average – What’s Next?

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.67 and traded as high as $1.05. Eagle Pharmaceuticals shares last traded at $0.80, with a volume of 19,398 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Eagle Pharmaceuticals in a report on Friday. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Up 22.5 %

The business’s 50 day moving average is $0.68 and its 200-day moving average is $2.40.

Institutional Trading of Eagle Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. DGS Capital Management LLC lifted its holdings in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the last quarter. Jane Street Group LLC acquired a new stake in Eagle Pharmaceuticals in the third quarter worth $96,000. RBF Capital LLC lifted its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals during the third quarter valued at $453,000. Finally, Creative Planning acquired a new position in shares of Eagle Pharmaceuticals during the third quarter valued at $59,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.